NCT06926205View on ClinicalTrials.gov

CHOP Plus Mosunetuzumab as First Line in Patients With Richter´s Syndrome: a Phase II Study of the Spanish Group of CLL

PHASE2RecruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

May 15, 2024

Primary Completion Date

May 15, 2028

Study Completion Date

May 15, 2028

Conditions
Richter Syndrome
Interventions
DRUG

Mosunetuzumab (IV)

6 cycle of Mosunetuzumab+CHOP and then 11 cycles more of mosunetuzumab on mnotherapy

Trial Locations (16)

15706

RECRUITING

Centro Hospitalario Universitario de Santiago, Santiago de Compostela

20014

RECRUITING

Hospital de Donostia, Donostia / San Sebastian

28006

RECRUITING

Hospital Universitario La Princesa, Madrid

28041

RECRUITING

Hospital Universitario 12 de Octubre, Madrid

29603

ACTIVE_NOT_RECRUITING

Hospital Universitario Costa del Sol, Marbella

30008

ACTIVE_NOT_RECRUITING

Hospital General Universitario Morales Meseguer, Murcia

33011

RECRUITING

Hospital Universitario Central de Asturias, Oviedo

35010

ACTIVE_NOT_RECRUITING

Complejo Hospitalario Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria

37007

ACTIVE_NOT_RECRUITING

Hospital Universitario de Salamanca, Salamanca

39011

RECRUITING

H Marqués de Valdecilla, Santander

41013

ACTIVE_NOT_RECRUITING

Hospital Universitario Virgen del Rocío, Seville

46010

ACTIVE_NOT_RECRUITING

Hospital Universitario Clínico de Valencia, Valencia

50009

ACTIVE_NOT_RECRUITING

Hospital Universitario Lozano Blesa, Zaragoza

08035

RECRUITING

Hospital Vall Hebron, Barcelona

08036

RECRUITING

Hospital Clínic y Porvincial de Barcelona, Barcelona

08908

RECRUITING

ICO Hospitalet Duran i Reynals, L'Hospitalet de Llobregat

All Listed Sponsors
collaborator

Evidenze Health España (CRO)

UNKNOWN

lead

GELLC (Grupo Español de Leucemia Linfocítica Crónica)

OTHER